The need for continued education is critical in these uncertain times. Therefore, the co-directors of the Fall Clinical Dermatology Conference are excited to announce our new program: the Fall Clinical Virtual Grand Rounds (FCVGR). This new online series is designed to help maintain the educational opportunities one would have if they were able to attend grand rounds in person.

FCVGR will consist of weekly CME sessions on a variety of dermatological diseases and tools.

This week, we will be coming to you LIVE!
Tuesday, June 30, 2020
7 PM EDT/ 4 PM PDT

EVOLVING CONCEPTS IN DERMATOLOGY PART IX

Directions in Dermatology and Their Impact on You: Patients, Practice, and Pharma Trends

Impact of COVID-19 on Dermatology Practices: A Survey of 1,000 US Dermatologists, Darrell S. Rigel, MD, MS
Dr. Rigel will be reviewing his survey of 1,000 US Dermatologists, that was recently published in JAAD. To review the article in advance of his presentation, you can access it here: https://www.jaad.org/article/S0190-9622(20)30913-0/pdf

Following the CME Presentation, a Special Industry Panel will discuss current directions and trends in the field:

Michael Braun, Vice President & Head, Immunology, Hepatology and Dermatology, Novartis

Bill Humphries, President, Ortho Dermatologics

Camille Lee, Senior Vice President & Head of US Immunology, UCB

Derek Maetzold, President and CEO, Castle Biosciences

Ron Menezes, President and GM, Almirall

Rebecca Morison, VP of Immunology, Lilly USA, LLC

Brian Mulnix, VP, US Marketing, Leo Pharma Inc.

Joe Sardano, President and CEO, Sensus Healthcare

Log in to Begin Activity

Darrell Rigel, MD, MS

Chair

Clinical Professor of Dermatology
New York University School of Medicine
The Ronald O. Perelman Department of Dermatology
New York, NY

Upon completion of this activity, the participant should be better able to:

Discuss the impact of COVID-19 on US Dermatology practices
Identify ways that patients, dermatologists, and Derm-related pharma have adapted to COVID-19 issues and how these will impact practice going forward.

This activity has been designed for dermatologists, dermatology physician assistants, dermatology nurse practitioners, and other providers involved in the care of patients.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Institute for Continuing Healthcare Education and the Foundation for Research and Education in Dermatology. The Institute is accredited by the ACCME to provide continuing medical education for physicians.

The Institute designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity is supported by educational grants from Almirall, Bristol-Myers Squibb, Lilly, Mayne Pharma, and UCB.

CONFLICTS OF INTEREST/DISCLOSURES

Darrell S. Rigel, MD, MS is a consultant for Castle Biosciences, DermTech, Ortho Dermatologics, Regeneron, and Scibase, and is on the speaker’s bureau for Almirall, Castle Biosciences, Ferndale, Johnson & Johnson, Myriad Genetics, Ortho Dermatologics, and Pfizer.

Cathy Pagano (Institute for Continuing Healthcare Education) has disclosed that she has no relevant financial relationships specific to the subject matter within the past 12 months.

Session 12 Evolving Concepts in Dermatology Part IX

Darrell Rigel, MD, MS

CONFLICTS OF INTEREST/DISCLOSURES

Session 12
Evolving Concepts in Dermatology Part IX